Cargando…

Apatinib-treated advanced medullary thyroid carcinoma: a case report

Medullary thyroid carcinoma (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. Neither radiotherapy nor chemotherapy has demonstrated durable objective responses in patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kan, Gao, Yun, Shi, Fei, Cao, Guangqiang, Bao, Jiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783142/
https://www.ncbi.nlm.nih.gov/pubmed/29403290
http://dx.doi.org/10.2147/OTT.S142598
_version_ 1783295241407692800
author Chen, Kan
Gao, Yun
Shi, Fei
Cao, Guangqiang
Bao, Jiandong
author_facet Chen, Kan
Gao, Yun
Shi, Fei
Cao, Guangqiang
Bao, Jiandong
author_sort Chen, Kan
collection PubMed
description Medullary thyroid carcinoma (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. Neither radiotherapy nor chemotherapy has demonstrated durable objective responses in patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine kinase inhibitors recently approved by the US Food and Drug Administration, which are not affordable for most Chinese patients. Herein, we report a case of an MTC patient who responded to apatinib, a Chinese homemade tyrosine kinase inhibitor-targeted vascular endothelial growth factor receptor. The patient was treated with thyroid lobectomy but developed MTC with extensive metastasis. The levels of serum calcitonin and carcino-embryonic antigen were much higher than the normal range. Apatinib was given at a dose of 500 mg daily and adjusted according to tolerance. Sixteen weeks following apatinib administration, the patient achieved a partial response, which lasted more than 9 weeks. No severe toxicity or drug-related side effect was observed during the treatment. Therefore, apatinib could be a new option for the treatment of advanced MTC.
format Online
Article
Text
id pubmed-5783142
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57831422018-02-05 Apatinib-treated advanced medullary thyroid carcinoma: a case report Chen, Kan Gao, Yun Shi, Fei Cao, Guangqiang Bao, Jiandong Onco Targets Ther Case Report Medullary thyroid carcinoma (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. Neither radiotherapy nor chemotherapy has demonstrated durable objective responses in patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine kinase inhibitors recently approved by the US Food and Drug Administration, which are not affordable for most Chinese patients. Herein, we report a case of an MTC patient who responded to apatinib, a Chinese homemade tyrosine kinase inhibitor-targeted vascular endothelial growth factor receptor. The patient was treated with thyroid lobectomy but developed MTC with extensive metastasis. The levels of serum calcitonin and carcino-embryonic antigen were much higher than the normal range. Apatinib was given at a dose of 500 mg daily and adjusted according to tolerance. Sixteen weeks following apatinib administration, the patient achieved a partial response, which lasted more than 9 weeks. No severe toxicity or drug-related side effect was observed during the treatment. Therefore, apatinib could be a new option for the treatment of advanced MTC. Dove Medical Press 2018-01-19 /pmc/articles/PMC5783142/ /pubmed/29403290 http://dx.doi.org/10.2147/OTT.S142598 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Chen, Kan
Gao, Yun
Shi, Fei
Cao, Guangqiang
Bao, Jiandong
Apatinib-treated advanced medullary thyroid carcinoma: a case report
title Apatinib-treated advanced medullary thyroid carcinoma: a case report
title_full Apatinib-treated advanced medullary thyroid carcinoma: a case report
title_fullStr Apatinib-treated advanced medullary thyroid carcinoma: a case report
title_full_unstemmed Apatinib-treated advanced medullary thyroid carcinoma: a case report
title_short Apatinib-treated advanced medullary thyroid carcinoma: a case report
title_sort apatinib-treated advanced medullary thyroid carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783142/
https://www.ncbi.nlm.nih.gov/pubmed/29403290
http://dx.doi.org/10.2147/OTT.S142598
work_keys_str_mv AT chenkan apatinibtreatedadvancedmedullarythyroidcarcinomaacasereport
AT gaoyun apatinibtreatedadvancedmedullarythyroidcarcinomaacasereport
AT shifei apatinibtreatedadvancedmedullarythyroidcarcinomaacasereport
AT caoguangqiang apatinibtreatedadvancedmedullarythyroidcarcinomaacasereport
AT baojiandong apatinibtreatedadvancedmedullarythyroidcarcinomaacasereport